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Background: The number of low birth weight infants with congenital heart disease is
increasing and catheterizations may have an increased risk for mortality and morbidity.
Objectives: We investigate the outcome and complications of cardiac catheterizations
in infants weighing<2.5 kg. Methods: Retrospective review of catheterization records
from 1995 to 2010 in infants weighing< 2.5 kg. The demographics, procedure, outcome,
and follow-up data were collected. Results: Of 101 catheterizations performed in 88
patients, 45 (45%) catheterizations were interventional. Balloon atrial septostomy
(n5 23), pulmonary valvuloplasty (14), aortic valvuloplasty (4), stent placement (3), bal-
loon angioplasty (2), and temporary pacemaker insertion (1) were successfully per-
formed. Balloon atrial septostomy was performed with pulmonary or aortic
valvuloplasty in two catheterizations. Infants<2.5 kg had higher significant adverse
event rate that those 2.523.5 kg (13% versus 6.6%, P<0.05). No procedural death was
noted. Significant adverse events (n5 13) included cardiopulmonary resuscitation
three, vascular six, arrhythmia three, and apnea requiring intubation one. On median
follow-up of 3 years (0.03 to 14), n5 69, mortality rate was 36%. In six patients with val-
var pulmonary stenosis with median follow-up of 6 years (0.75–13), four (67%) did not
require re-intervention. Of two patients with aortic stenosis, one did not require repeat
intervention for 6 years (last follow-up). Conclusion: Interventional catheterization is
feasible with low procedural morbidity and mortality in high risk infants<2.5 kg. Cathe-
terization primarily serves as a palliative procedure to stabilize infants for definitive
treatment. Balloon valvuloplasty may be effective for isolated valvar pulmonary steno-
sis in infants<2.5 kg. VC 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Infants with congenital heart disease (CHD) have a
higher incidence of low birth weight (LBW) [1]. In the
current era of improved neonatal care, mortality of LBW
infants continues to decline [2]. However, mortality for
premature and LBW infants undergoing surgery for CHD
remain high [3,4]. Therefore, catheter-based interventions
as a palliative and therapeutic option have been increas-
ingly utilized to improve the outcome of these high risk
infants. Furthermore, technical feasibility, outcome and
complications of cardiac catheterization continue to be a
concern because of small infant size and weight. Few
large studies reporting their catheterization experience
have shown increased risk of mortality and vascular com-
promise in LBW infants [5–7]. However, the long term
outcome of high risk LBW infants with complex CHD
undergoing catheterization has not been adequately
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evaluated. We report the acute- and long-term outcome,
and significant adverse events (SAE) of cardiac catheter-
izations in infants weighing< 2.5 kg from a single center.
MATERIALS AND METHODS
Retrospective review of patients weighing< 2.5 kg
who underwent cardiac catheterization from 1995 to 2010
was performed with the approval from Institutional
Review Board. The catheterization reports, medical
records, procedural, and follow-up data were reviewed in
all patients. The study group was divided by procedure
types as diagnostic or interventional for analysis. The
angioplasty of pulmonary and aortic valve was performed
using standard techniques similar to that in larger infants.
The balloon size for balloon pulmonary valvuloplasty
(BPV) and balloon aortic valvuloplasty (BAV) was cho-
sen with ratio of balloon diameter to the annulus being
100–150% and 80–100%, respectively. The procedural
success based on specific intervention were defined as;
Balloon atrial septostomy (BAS)—decrease in gradient
across the atrial septum, or improved oxygen saturation,
or improved flow across the atrial septum by echocardi-
ography. BPV–decreased right ventricle / systemic pres-
sure ratio, or improved flow across the pulmonary valve
with ability to successfully wean off prostaglandins.
BAV—increased forward flow through the aortic valve,
decrease in gradient of at least 40% and/or ability to wean
prostaglandin infusion or inotropic support [8]. Stenotic
vessel angioplasty/stent–improvement in stenotic segment
greater than 50% of its original size or improved contrast/
blood flow. Regarding anticoagulation during the cathe-
terization, intravenous heparin (initial dose 75100 units
per kg) was routinely used for interventional left heart
catheterization, and activated clotting time was monitored
every 30 minutes to maintain activated clotting time lon-
ger than 250 seconds. However, heparin was not always
used for diagnostic or interventional right heart catheteri-
zation. Head ultrasound was routinely obtained in the
neonatal intensive care unit prior to the catheterization
and heparin was avoided for elevated baseline activated
clotting time. SAE was defined as death, cardiopul-
monary resuscitation, and complications including hemo-
dynamic instability, respiratory compromise, cardiac
perforation, vascular injury, blood loss, arrhythmias, atri-
oventricular block, and others that caused significant mor-
bidity, leading to medical and surgical interventions, and/
or extended length of stay. As a reference, we collected
the SAE data in infants weighing 2.53.5 kg undergoing
cardiac catheterization during the same study period.
Long-term follow-up data were divided into two groups:
(1) intervention as a primary therapeutic option (BAV
and BPV), and (2) diagnostic and or intervention as a pal-
liative procedure. Statistical analysis was performed using
SPSS software for PC (version 19.0) (SPSS, Chicago,
IL). Continuous variables were reported as median and
range, and nominal variables were reported as number
(percentage). Independent student’s t test and Chi-square
test were used to compare parameters between groups.
RESULTS
Patients and Diagnoses
We identified 101 catheterizations in 88 patients
weighing< 2.5 kg at the time of procedure. Of these, 56
were diagnostic and 45 catheterizations were interven-
tional procedures. At the catheterization, the median
(range) age, gestational age, and weight was 9 days
(097), 34 weeks (2839), and 2.2 kg (0.982.5),
respectively (Supporting Information Table I). The most
common diagnoses (Supporting Information figure) are
transposition of great arteries, n¼ 13, followed by PS
11, hypoplastic left heart syndrome eight, double outlet
right ventricle eight, pulmonary atresia with intact ven-
tricular septum eight, pulmonary atresia with ventricular
septum defect eight, tetralogy of Fallot seven, and inter-
rupted aortic arch six. Forty five interventions were
performed in 41 patients (Fig. 1). The most common
interventions were BAS and/or atrial septal dilation,
n¼ 23, BPV, n¼ 14, and BAV, n¼ 4. As compared to
venous access obtained in 93% of catheterizations, arte-
rial access was obtained in 25%.
Hemodynamics and Interventions
Patient demographics and comparison between the
diagnostic and interventional groups (Supporting Infor-
mation Table I). Technical characteristics, hemodynam-
ics, and interventions are summarized in Tables I and II.
The diagnostic procedures were performed to delineate
pulmonary arterial anatomy, confluence, collaterals, and
pulmonary venous drainage. The most common interven-
tions were BAS, and angioplasty of aortic and pulmonary
valves. All interventions were acutely successful. BPV
was performed in 14 patients (Table I). The ratio of sys-
tolic right ventricle pressure to systolic systemic pressure
was significantly decreased after BPV in most patients.
However, hemodynamic assessment of right-sided pres-
sures might be affected by the presence of widely open
ductus arteriosus. Six patients underwent BPV for iso-
lated valvar PS. Remaining eight patients had complex
PS with associated other CHD and/or additional sub and
supravalvar stenosis (Table I). BAV was performed suc-
cessfully in four patients (Table I). Three patients under-
went BAV for isolated valvar AS. Twenty-three BAS
and/or atrial septal dilation were performed in 20 patients
successfully and three patients required repeat
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septostomy prior to palliative or definitive surgery (Table
II). The remaining interventions are listed in Table II.
Complications
Table III summarizes the SAE in infants
weighing<2.5 kg. The overall SAE rate in infants
weighing< 2.5 kg was higher than that in those weigh-
ing 2.53.5 kg (13% versus 6.6%, P< 0.05, Support-
ing Information Table II). The incidence of vascular
complications was significantly higher in infants
weighing< 2.5 kg than those weighing 2.5–3.5 kg (6%
vs. 0.9%, P< 0.05). Among the infants< 2.5 kg, the
SAE rates between diagnostic and interventional
groups were comparable (11% vs. 16%, P 5 0.56).
There was no procedural death. Cardiopulmonary
resuscitation was performed briefly in three patients
among the interventional group and they continued to
have successful procedure. One patient (Pt 7) with val-
var PS had endotracheal tube displacement and brady-
cardia requiring chest compression and re-intubation
followed by successful angioplasty. The second patient
(Pt 13), following BPV had cardiac arrest requiring
resuscitation with chest compression and one dose of
epinephrine. The third patient (Pt 39), following stent
placement in vertical vein for obstructed total anoma-
lous pulmonary venous return experienced bradycardia
because of inadvertent extubation requiring chest com-
pression and re-intubation. Arrhythmia (n¼ 3) included
supraventricular tachycardia treated with adenosine in
two patients (Pt 31) and transient heart block requiring
no intervention in one patient. Among vascular com-
promise (n¼ 6), three patients were treated with hepa-
rin for lost femoral arterial pulse (Pt 2). All of them
recovered with good perfusion and recovery of distal
pulses 48 hrs later. Two had vascular injury to inferior
vena cava (IVC); one patient (Pt 5) underwent pulmo-
nary angioplasty and repeat catheterization for BPV
revealed intimal damage of hepatic portion of IVC.
This did not require any intervention and was pre-
sumed to be related to previous catheterization. Second
patient underwent diagnostic catheterization for severe
PS, patent ductus arteriosus and multiple ventricular
septal defects without complications. One week later
repeat catheterization was performed for desaturations
to attempt BPV. This revealed IVC occlusion below re-
nal veins and BPV was performed with right internal
jugular venous approach. IVC thrombus was presumed
to be related to prior catheterization and extension of
thrombus from right femoral vein or related to previous
umbilical venous line placement. One patient (Pt 33)
with hypoplastic left heart syndrome following Hybrid
stage 1 procedure underwent BAS for atrial restriction
using right femoral vein. Three weeks later, a stent
was placed for re-coarctation using left femoral vein
prograde allowing controlled stent delivery through a
large sheath and to prevent arterial vessel injury.
Repeat catheterization 3 weeks later for recurrent atrial
restriction revealed bilateral femoral vein occlusion
requiring stent placement in the atrial septum using
Hybrid approach. On further review, among six
patients with vascular compromise, heparin was admin-
istered in only one patient with IVC damage. Head
ultrasound on all patients was normal and heparin was
withheld in one because of prolonged baseline ACT. In
the remaining four patients, heparin was not given
based on the operating physician’s preference.
Long-Term Outcomes
The long-term outcome is summarized in Fig. 2.
Follow-up data were available in 69 patients (78%),
with a median follow-up of 3 years (range: 2 weeks to
14 years). In the intervention group; with a median fol-
low up of 7 years (range: 9 months–13 years), five of
46 patients (10%), four with isolated valvar PS and
one with valvar aortic stenosis have been hemodynami-
caly stable without need for re-intervention at last
follow-up. The remaining patients had re-intervention/
definitive or staged surgical palliation (n¼ 30) and
total deaths (n¼ 11) (Tables I and II). In the diagnostic
group; 32 of 45 patients were available for follow-up.
Twenty-five patients underwent palliative or corrective
surgery and 17 (53%) were doing well at last follow-
Fig. 1. Interventions. BPV, balloon pulmonary valvuloplasty;
BAS, balloon atrial septostomy; BAV, balloon aortic valvulo-
plasty. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
804 Kobayashi et al.
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
up. There were eight deaths in this group of various
causes. In addition, there were six deaths in patients
awaiting initial treatment. In the entire cohort available
for follow-up (n¼ 69), there were total of 25 deaths
(36%); complex CHD comprising Tetralogy of Fallot
or double outlet right ventricle associated with pulmo-
nary atresia and hypoplastic pulmonary arteries were
the majority 10 (40%), followed by single ventricle pa-
thology six (24%) and CHD associated with chromo-
somal anomalies in six (24%) patients. Figure 2
summarizes various causes of death with sepsis, nectro-
tizing enterocolitis, hypoxemia, heart failure with
multi-organ failure as leading cause for mortality.
DISCUSSION
Catheter interventions in LBW infants have been
facilitated with rapid advances in cardiac catheteriza-
tion techniques, miniaturization, and improvement in
catheter design and equipment. Although surgical out-
come of CHD continues to improve in LBW infants,
there is still significant morbidity and mortality [3,4].
Catheter interventions can palliate those high risk
infants to optimize weight gain, leading to successful
surgery with less morbidity and mortality. Our cohort
had near equal share of interventional (44%) and diag-
nostic catheterization (56%) procedures. There was no
procedure related deaths. Intervention predominantly
TABLE I. Balloon Valvuloplasty
Pt Wt (kg) Age (day) Diagnoses
Re-intervention Last follow-up
Age Type Age
ECHO findings
(Grad PV mm Hg)
Balloon pulmonary valvulopalsty
1 1.0 11 Isolated valvar PS None 13y Alive
Mild PI, Grad 21
2 2.3 0 Isolated valvar PS None 8y Alive
No PI, Grad 16
3 1.6 1 Isolated valvar PS None 7y Alive
Trivial PI, no PS
4 1.6 35 Isolated valvar PS None 9m Alive
Mild PI, Grad 22
5 1.6 1 Isolated valvar PS 78d BPV 6y Alive
6m surgery Free PI, no PS
6 1.6 3 Isolated valvar PS 45d BPV 16m Alive
Trivial PI, Grad 20
7 2.2 69 Sub/Supravalvular PS 84d Surgery 7m Alive
Free PI, no PS
8 2.5 15 Supravalvular PS / AS, Williams* 4m Surgery 11y Alive
Mod PI, Grad 21
9 1.2 27 Valvar/subvalar PS 7m BPV 7m Alive
Free PI, Grad 31
10 1.8 13 DORV,PS,Goldernhar’s Lost to follow-up
11 2.5 11 VSD, PS 8m Surgery 10m Alive
Free PI, Grad 19
12 2.4 13 VSD, ASD, ASD, PS 16d Surgery 3y Alive
Free PI, no PS
13 2.1 66 VSD, PS, Trisomy 10, monosomy 5 99d Surgery 170d Death
14 1.9 32 TOF, PS, Trisomy 18 None 35d Death
Pt Wt (kg) Age (day) Diagnoses
Re-Intervention Last follow-up
Age Type Age Comment
Balloon aortic valvulopalsty
15 2.3 90 Isolated valvar AS None 6y Alive
Trivial AI, no AS
16 2.5 2 Isolated valvar AS 68d Surgery 8y Alive
17 2.2 1 Isolated valvar AS Lost follow-up
18 2.5 97 HLHS, EFE 163d BAV 6y Alive
182d OHT
Pt 10 underwent concomitant balloon atrial septostomy at the same catheterization. Pt 18 underwent concomitant balloon atrial septostomy at the
same catheterization.
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served as a palliative procedure (89%) and was cura-
tive in small number of patients with isolated valvar
PS and AS (11%). The long-term mortality for the
entire cohort was 36%.
BPV has an excellent long-term follow-up outcome
in children [9]. However, there is scanty follow-up
data of BPV in LBW infants. Simpson et al. reported
the follow-up data of BPV in eight infants
weighing 2.5 kg with isolated valvar PS [6]. In a me-
dian follow-up of 31 months (range 1 month to 10
years), the re-intervention rate was 71% (5/7) at 1
year. Authors concluded that BPV should be regarded
as an initial palliation because most patients require
additional dilation as they grow. In contrast, our study
showed 67% (4/6) patients with isolated valvar PS did
not require re-intervention at longer median follow-up
of 6 years (Table I). Our data may suggest BPV can be
a definitive therapy even in LBW infants with isolated
TABLE II. Other Interventions
Pt Weight (kg) Age (day) Diagnoses Surgery
Last follow-up
Age Outcome
Balloon Atrial Septostomy and Atrial Septal Dilation
10 1.8 13 DORV, PS Lost to follow-up
18 1.9 22 HLHS, EFE OHT (182 do) 6y Alive
2.5 97
19 1.4 4 Tricuspid atresia PAB (38 do), Hemi-Fontan
(10 mo), Fontan (2 yo)
3y Alive
20 2.3 3 PA/IVS, RVDCA mBTS (11 do), Hemi-Fontan
(6 mo), Fontan (2yo)
8y Alive
21 1.7 1 TGA ASO (20 do) 5y Alive
22 2 3 TGA OHT (61 do) 11y Alive
23 2.3 0 TGA ASO (7 do) 3y Alive
24 2.4 12 TGA ASO (124 do) 7y Alive
25 2.5 3 TGA ASO (9 do) 7y Alive
26 2.5 3 TGA ASO (18 do) 11y Alive
27 2.1 6 TGA ASO (32 do) 11m Alive
2.1 8
28 2 0 TGA ASO (40 do) 11y Alive
2 31
29 1.8 14 PA/IVS, RVDCA NA 10y Alive
30 1.6 5 TGA None 14d Death
31 1.9 8 TGA, IAA ASO, arch repair (40 do) 86d Death
32 2.3 3 PA/IVS, MAPCA Unifocalization, systemic-pulm
shunt (40do)
70d Death
33 1.5 22 HLHS Stent on Coarctation (41 do),
Hybrid (56 do)
111d Death
34 1.9 31 HLHS Norwood (63 do) 63d Death
35 1.8 13 Tricuspid atresia Norwood (33 do) 21m Death
36 2.5 2 Tricuspid atreisa, PA Lost to follow-up
Pt Wt (kg) Age (day) Diagnoses
Intervention
Surgery
Last follow-up
Type Site Balloon / Stent (mm) Age Outcome
Other interventions
37 2.2 58 HLHS, s/p Hybrid,
CHARGE
Angioplasty LIV 2x25 None 63d Death
Angioplasty Coarctation 4x20
38 2.5 32 HLHS, s/p Norwood Angioplasty BTS 4x20 None 37d Death
2.5 33 HLHS, s/p Norwood Stent mBTS Vision coronary 3.5x12
39 1.4 9 Obstructed TAPVR Stent Vertical vein Vision coronary 12x40 Lost to follow-up
40 2.3 5 TOF, PA, LPA stenosis Stent LPA Vision coronary 4x12 Rastelli
(198d)
6y Alive
41 2.5 23 Cardiomyopathy Pacemaker RV Brad bipolar pacing lead None 53d Death
Balloon atrial septostomy and atrial septal dilation: 23 interventions were performed in 20 patients. Three patients (Pt 18, 27, 28) had repeat balloon atrial
septostomy. Pt 10 underwent balloon pulmonary vavuloplasty and Pt 18 underwent balloon aortic valvuloplasty at the same catheterization. Other inter-
ventions: Six interventions were performed in five patients. One patient (Pt 38) underwent two interventions such as angioplasty and stent placement.
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valvar PS. BAV is effective for relief of congenital
AS. Infants who underwent BAV within 30 days of
life had significantly higher hazard (hazard ratio 5.3)
for repeat balloon dilation, though follow-up data of
this procedure in LBW infants is limited [10]. Sutton
et al. reported four patients with BAV [8]. One patient
did not require re-intervention and had mild aortic re-
gurgitation and stenosis at 4.5-year-old. In our study,
of the two patients with isolated AS, one patient did
not require repeat intervention or surgery at 6 years of
age. Regarding other interventions, BAS and dilation
were palliative with subsequent shunt or arterial switch
procedure. In our study, 94% (17/18) underwent subse-
quent definitive or palliative surgery; only one patient
(6%) died prior to surgery. Our results are comparable
to results from previous studies [7]. Diagnostic proce-
dures were predominantly performed to evaluate anat-
omy and were helpful in evaluating pulmonary arterial
and venous anatomy, thus playing a crucial role in
planning future surgical or palliative treatment.
Previous studies have consistently reported a higher
prevalence of CHD in preterm infants and still birth,
suggesting potential causal relationship, though its
exact cause and effect is poorly understood [1,11].
Although increased prenatal detection of CHD poten-
tially leads to induction of labor and elective cesarean
section before term, premature delivery is generally not
recommended [11]. More recently, Laas et al. showed
a significantly higher risk (odds ratio 2.0) of preterm
birth in infants with CHD in a large population based
study, because of an increase in spontaneous preterm
birth with no evidence of an increase in induced labor
or cesarean delivery before labor [12]. Our finding of
twice higher SAE rate in infants weighing less than 2.5
kg as compared to that in infants weighing 2.5–3.5 kg
is not surprising, as several studies have shown signifi-
cantly higher early morbidity and mortality in prema-
ture infants [4,13]. The precise mechanisms
predisposing LBW infants to adverse outcomes are not
known. However, postulated explanations include phys-
iologic role of nitric oxide and surfactant production,
and fetal lung fluid clearance in the final weeks of
pregnancy in postnatal lung function. Incomplete matu-
ration of lungs, central nervous system and other organ
system in LBW infants with CHD are additional fac-
tors [3,13]. The vascular complications were signifi-
cantly higher in LBW infants in our cohort, likely
because of a smaller vessel caliber, variable use of
heparin and its anticoagulant effects in neonates. The
arterial complications were likely under-represented in
infants weighing< 2.5 kg as left heart intervention
were less frequent. Interestingly, the respiratory com-
plications were not significantly different. This could
be because of elective use of endotracheal intubation
in most cases of LBW infants.
Several studies have reported that the complications
related to cardiac catheterization in infants
weighing 2.5 kg ranged from 26% to 56% [4–7].
Complications were more often seen in interventional
than in diagnostic catheterization. The most common
complications during interventions were arrhythmia,
vascular injury and major complications included respi-
ratory deterioration and death [5–8]. In our study, the
SAE rates between diagnostic and interventional cathe-
terizations were not statistically different (11% vs.
16%), because of low overall SAE rate and a limited
sample size. There was no catheterization-related mor-
tality in our study. Infants with LBW because of pre-
mature lungs, lower lung compliance, and edematous
lungs are at increased risk of respiratory compromise
[7]. Not surprisingly, respiratory issues were responsi-
ble for the majority of complications requiring cardio-
pulmonary resuscitation. Elective endotracheal
intubation to protect and maintain stable airway as
well as frequent procedural checks to avoid accidental
extubation should be a routine practice. Monitoring
TABLE III. Significant Adverse Events in Infants Weighing<2.5 kg
Comment
Total
(n¼ 101)
Diagnostic
Group (n¼ 56)
Interventional
Group (n¼ 45) P value
Death 0 0 0 NS
CPR 3 0 3
Arrhythmia SVT treated with adenosine 2 1 1
SVT and transient heart block 1 1 0
Vascular Arterial Lost femoral pulses treated with heparin 3 2 1
Venous Occlusion / damage to IVC 2 1 1
Bilateral femoral vein occlusion 1 0 1
Respiratory Apnea requiring intubation 1 1 0
Total 13 (13%) 6/55 (11%) 7/46 (16%) 0.56
CPR, cardiopulmonary resuscitation; IVC, inferior vena cava; SVT, supraventricular tachycardia. Interventional group: CPR (Pt 7, 13 and 39),
arrhythmia (Pt 31), vascular arterial (Pt 1), vascular venous (Pt 5 and 33).
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airway during the procedure is performed by either the
catheterization laboratory nurse or anesthesia team
based on primary personnel responsible for sedation
and airway management. Vascular complications were
similar to previously reported studies. Interestingly, we
found two cases of IVC thrombosis and one case of
bilateral femoral vein thrombosis following catheteriza-
tion and these were noted in subsequent catheteriza-
tion. Among six infants weighing< 2.5 kg with
vascular complications, five (83%) had no heparin
use during the catheterization. Optimization of anticoa-
gulation may be one of the preventive measures to
reduce the risk of vascular complications in LBW
infants undergoing catheterization. Screening with pre-
procedural head ultrasound, coagulation profile prior to
use of standard procedural heparin dose with regular
ACT checks may be prudent even in infants under-
going diagnostic or interventional right heart catheteri-
zation. Moreover, anticoagulant effect of heparin can
be impaired in neonates because of much lower level
of endogenous anticoagulant antithrombin [14].
Recently, a newer direct thrombin inhibitor, Bibaliru-
bin, was studied in pediatric patients (including neo-
nates) undergoing catheterizations [15]. Bibalirubin had
Fig. 2. Long-term outcome of 88 patients<2.5 kg (101 cathe-
terizations). ASD, atrial septal defect; AVCD, atrioventricular
canal defect; BTS, Blalock-Taussig shunt; CoA, coarctation of
aorta; DKS, Damus-Kaye-Stansel procedure; DORV, double
outlet right ventricle; ECMO, extracorporeal membrane oxy-
genation; f/u, follow up; HLHS, hypoplastic left heart syn-
drome; HP, hospital; IAA, interrupted aortic arch; influ B,
influenza virus type B; IUGR, intrauterine growth retardation;
IVS, intact ventricular septum; LMBTS, left modified Blalock-
Taussig shunt; MAPCA, major aortopulmonary collateral
arteries; NA, not available; NEC, necrotizing enterocolitis; PA,
pulmonary atresia; PA angiopl, pulmonary artery angioplasty;
PAPVR, partial anomalous pulmonary venous return; PDA,
patent ductus arteriosus, PS, pulmonary stenosis; RF, respira-
tory failure; RSV, respiratory syncytial virus; SVT, supraventric-
ular tachycardia; TOF, Tetralogy of Fallot; VSD, ventricular
septal defect; TGA, transposition of great arteries. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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shorter and more predictable half-life with no increased
risk of bleeding complications or other safety concerns.
Therefore, Bibalirubin may be a potential alternative to
heparin to reduce the risk of vascular complications in
LBW infants.
Various factors for early mortality in LBW infants
have been extensively reported and included low
Apgar scores <5, prolonged mechanical ventilation,
greater surgical complexity, prolonged cardiopulmo-
nary bypass time, increased risk of infection, small
size of cardiovascular structures with immaturity of
myocyte calcium handling proteins, need for postoper-
ative cardiopulmonary resuscitation, use of ECMO,
associated major congenital anomalies, diagnosis of
hypoplastic left heart syndrome and its variants [3,4].
In our heterogeneous group of LBW infants, the pri-
mary focus was catheterization-based intervention and
its outcome. Thus, assessing factors for early and late
surgical mortality was beyond the scope of this study.
Following catheterization, most of the patients under-
went further surgical palliative or complete repair.
The early mortality rate in LBW/premature infants is
significantly higher than that in term infants. Costello
et al. reported a higher mortality rate in premature
infants in a large cohort of 971 patients with CHD
(3% for 38–39 weeks gestation, 7% for 37–38 weeks,
and 32% for <34 weeks gestation). In addition, LBW
infants were associated with greater rate of fetal com-
promise, CHD, and chromosomal anomalies. [13].
The primary strategies employed to reduce mortality
in LBW infants are (1) early surgical approach that
offers benefits of avoiding hemodynamic effects and
secondary damage to end organs and (2) delayed sur-
gery to allow weight gain and to attain mature gesta-
tional age. The outcomes in either strategy are not
significantly different. Cheng et al. reported a high in-
hospital mortality of 18% and 5-year mortality of
23% in 174 premature infants with critical CHD who
underwent cardiac interventions (including surgery
and catheter intervention) during the first month of
life [4]. In contrast, our institutional strategy for LBW
infants is delayed surgical approach assisted by medi-
cal management and catheterization-based interven-
tion prior to definitive or staged surgical palliative
approach. We report early mortality of 19% and over-
all mortality of 36% with a median follow-up of 3
years in our cohort. This is similar to other studies
from institutions advocating early repair with early
mortality ranging from 15% to 42% [3,4,16,17]. Our
low catheterization-related complication rate and ac-
ceptable overall mortality augur well to delayed surgi-
cal approach employed by our and other institutions
in treating LBW infants with complex CHD.
Our study was conducted retrospectively and could
underestimate the SAE rates. The late complication
rate of vessel injury is unknown, because of no routine
imaging study of access vessels after the catheteriza-
tion. However, the vessel injuries found in the follow-
ing catheterization were included in our study.
Furthermore, all infants within 48 hours of procedure
with adverse events were routinely reported and eval-
uated in neonatal intensive care unit, thus eliminating
under-reporting of any procedure related SAE. Our
data regarding long-term survival and mortality may be
higher than reported as we had follow-up information
available only in 78% of patients. Nevertheless, this
study highlights a large cohort of LBW infants under-
going catheterization in a single center with minimal
complications compared to previous studies
(during similar time frame) and no catheterization-
related mortality.
CONCLUSIONS
Interventional catheterization is technically feasible
with relatively low morbidity and mortality in high
risk infants weighing less than 2.5 kg. In most infants
catheterization primarily serves as a palliative proce-
dure to stabilize infants for definitive treatment. How-
ever, balloon valvuloplasty may be an effective
treatment for small group of isolated valvar pulmonary
stenosis. The long-term mortality in these high-risk
infants remains high.
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